Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | UBE2C |
| Gene Name: | UBE2C |
| Protein Full Name: | Ubiquitin-conjugating enzyme E2 C |
| Alias: | Ubiquitin-protein ligase C |
| Mass (Da): | 19634 |
| Number AA: | 179 |
| UniProt ID: | O00762 |
| Locus ID: | 11065 |
| COSMIC ID: | UBE2C |
| Gene location on chromosome: | 20q13.12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19807 |
| Percent of cancer specimens with mutations: | 0.15 |
| Normal role description: | Ubiquitination protein. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit. Upregulation of this gene has been observed in brain, bladder, breast, cervical, liver, lung, ovarian, prostate, stomach, and thyroid tumors. |